Hostname: page-component-78c5997874-lj6df Total loading time: 0 Render date: 2024-11-10T23:09:32.607Z Has data issue: false hasContentIssue false
  • English
  • Français

Haematological factors in the management of adult epistaxis: systematic review

Published online by Cambridge University Press:  27 December 2017

A Williams ,
A Biffen ,
N Pilkington ,
L Arrick ,
R J Williams ,
M E Smith ,
M Smith  and
J Birchall
A Williams*
Affiliation:
Department of Anaesthesia, Derriford Hospital, Plymouth, UK
A Biffen
Affiliation:
Department of Anaesthesia, Derriford Hospital, Plymouth, UK
N Pilkington
Affiliation:
Department of Anaesthesia, Derriford Hospital, Plymouth, UK
L Arrick
Affiliation:
Department of Anaesthesia, Derriford Hospital, Plymouth, UK
R J Williams
Affiliation:
Institute of Naval Medicine, Gosport, UK
M E Smith
Affiliation:
Department of Otolaryngology, Addenbrooke's Hospital, Cambridge, UK
M Smith
Affiliation:
Exeter Health Library, Peninsula Medical School, UK
J Birchall
Affiliation:
Department of Haematology, North Bristol NHS Trust, NHS Blood and Transplant, Bristol, UK
*
Address for correspondence: Dr Ashleigh Williams, Department of Anaesthesia, Derriford Hospital, Plymouth PL6 8DH, UK E-mail: ashleighwilliams@nhs.net
Get access Rights & Permissions [Opens in a new window]

Abstract

Background:

The management of epistaxis requires an understanding of haematological factors that may complicate its treatment. This systematic review includes six distinct reviews examining the evidence supporting epistaxis-specific management strategies relating to warfarin, direct oral anticoagulants, heparin, antiplatelet agents, tranexamic acid and transfusion.

Method:

A systematic review of the literature was performed using a standardised methodology and search strategy.

Results:

Limited numbers of articles were identified in each systematic review, with level 1 evidence only regarding the use of tranexamic acid. No studies met the inclusion criteria within the heparin, direct oral anticoagulants or transfusion systematic reviews. Many studies were limited by small sample sizes and significant risk of bias.

Conclusion:

The management of major bleeding and transfusion practice is well documented in national guidance from multiple sources. The guidelines include advice on anticoagulants, antiplatelet agents and tranexamic acid. In the absence of more specific evidence, these guidelines should be applied in the management of epistaxis.

Keywords

EpistaxisTherapyCoumarinsHeparinBlood
Type
Review Articles
Information
The Journal of Laryngology & Otology , Volume 131 , Issue 12 , December 2017 , pp. 1093 - 1107
Copyright
Copyright © JLO (1984) Limited 2017 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1 Rainsbury, JW, Molony, NC. Clopidogrel versus low-dose aspirin as risk factors for epistaxis. Clin Otolaryngol 2009;34:232–5Google Scholar
2 Goddard, JC, Reiter, ER. Inpatient management of epistaxis: outcomes and cost. Otolaryngol Head Neck Surg 2005;132:707–12Google Scholar
3 Murer, K, Ahmad, N, Roth, BA, Holzmann, D, Soyka, MB. THREAT helps to identify epistaxis patients requiring blood transfusions. J Otolaryngol Head Neck Surg 2013;42:4 Google Scholar
4 Pollice, PA, Yoder, MG. Epistaxis: a retrospective review of hospitalized patients. Otolaryngol Head Neck Surg 1997;117:49–53 Google Scholar
5 Khan, M, Conroy, K, Ubayasiri, K, Constable, J, Smith, ME, Williams, RJ et al. Initial assessment in the management of adult epistaxis: systematic review. J Laryngol Otol. In pressGoogle Scholar
6 Daniels, PR. Peri-procedural management of patients taking oral anticoagulants. BMJ 2015;351:h2391 CrossRefGoogle ScholarPubMed
7 Keeling, D, Baglin, T, Tait, C, Watson, H, Perry, D, Baglin, C et al. ; British Committee for Standards in Haematology. Guidelines on oral anticoagulation with warfarin – fourth edition. Br J Haematol 2011;154:311–24CrossRefGoogle ScholarPubMed
8 Denholm, SW, Maynard, CA, Watson, HG. Warfarin and epistaxis–a case controlled study. J Laryngol Otol 1993;107:195–6CrossRefGoogle ScholarPubMed
9 Smith, J, Siddiq, S, Dyer, C, Rainsbury, J, Kim, D. Epistaxis in patients taking oral anticoagulant and antiplatelet medication: prospective cohort study. J Laryngol Otol 2011;125:38–42 Google Scholar
10 Srinivasan, V, Patel, H, John, DG, Worsley, A. Warfarin and epistaxis: should warfarin always be discontinued? Clin Otolaryngol 1997;22:542–4Google Scholar
11 Bola, S, Marsh, R, Braggins, S, Potter, C, Hickey, S. Does the continuation of warfarin change management outcomes in epistaxis patients? J Laryngol Otol 2016;130:256–60Google Scholar
12 NICE Clinical Knowledge Summary. Anticoagulation: oral. In: https://cks.nice.org.uk/anticoagulation-oral [30 May 2017]Google Scholar
13 Burnett, AE, Mahan, CE, Vazquez, SR, Oertel, LB, Garcia, DA, Ansell, JA. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis 2016;41:206–32CrossRefGoogle ScholarPubMed
14 European Medicines Agency. Pradaxa® – Summary of Product Characteristics. 2015. In: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf [30 May 2017]Google Scholar
15 Keeling, D, Tait, RC, Watson, H. Peri-operative management of anticoagulation and antiplatelet therapy. Br J Haematol 2016;175:602–13Google Scholar
16 Makris, M, Van Veen, JJ, Tait, CR, Mumford, AD, Laffan, M; British Committee for Standards in Haematology. Guideline on the management of bleeding in patients on antithrombotic agents. Br J Haematol 2013;160:35–46 CrossRefGoogle ScholarPubMed
17 Callejo, FJ, Martínez, CB, González, JC, Beneyto, PM, Sanz, MM, Algarra, JM. Epistaxis and dabigatran, a new non-vitamin K antagonist oral anticoagulant. Acta Otorrinolaringol Esp 2014;65:346–54CrossRefGoogle Scholar
18 Pahs, L, Beavers, C, Schuler, P. The real-world treatment of hemorrhages associated with dabigatran and rivaroxaban: a multicenter evaluation. Crit Pathw Cardiol 2015;14:53–61 Google Scholar
19 Tay, HL, McMahon, AD, Evans, JM, MacDonald, TM. Aspirin, nonsteroidal anti-inflammatory drugs, and epistaxis. A regional record linkage case control study. Ann Otol Rhinol Laryngol 1998;107:671–4Google Scholar
20 Soyka, MB, Rufibach, K, Huber, A, Holzmann, D. Is severe epistaxis associated with acetylsalicylic acid intake? Laryngoscope 2010;120:200–7Google Scholar
21 Biggs, TC, Baruah, P, Mainwaring, J, Harries, PG, Salib, RJ. Treatment algorithm for oral anticoagulant and antiplatelet therapy in epistaxis patients. J Laryngol Otol 2013;127:483–8CrossRefGoogle ScholarPubMed
22 Estcourt, LJ, Birchall, J, Allard, S, Bassey, SJ, Hersey, P, Kerr, JP et al. ; British Committee for Standards in Haematology. Guidelines for the use of platelet transfusions. Br J Haematol 2017;176:365–94Google Scholar
23 Joint United Kingdom (UK) Blood Transfusion and Tissue Transplantation Services Professional Advisory Committee. National Blood Transfusion Committee Responses and Recommendations. In: http://www.transfusionguidelines.org/uk-transfusion-committees/national-blood-transfusion-committee/responses-and-recommendations [30 May 2017]Google Scholar
24 Napolitano, LM, Cohen, MJ, Cotton, BA, Schreiber, MA, Moore, EE. Tranexamic acid in trauma: how should we use it? J Trauma Acute Care Surg 2013;74:1575–86CrossRefGoogle ScholarPubMed
25 Roberts, I, Shakur, H, Coats, T, Hunt, B, Balogun, E, Barnetson, L et al. The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. Health Technol Assess 2013;17:1–79 Google Scholar
26 WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet 2017;389:2105–16CrossRefGoogle Scholar
27 NICE Guideline 24. Blood Transfusion. 2015. In: https://www.nice.org.uk/guidance/ng24 [30 May 2017]Google Scholar
28 Tibbelin, A, Aust, R, Bende, M, Holgersson, M, Petruson, B, Rundcrantz, H et al. Effect of local tranexamic acid gel in the treatment of epistaxis. ORL J Otorhinolaryngol Relat Spec 1995;57:207–9Google Scholar
29 Zahed, R, Moharamzadeh, P, Alizadeharasi, S, Ghasemi, A, Saeedi, M. A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial. Am J Emerg Med 2013;31:1389–92Google Scholar
30 Petruson, B. Epistaxis. A clinical study with special reference to fibrinolysis. Acta Otolaryngol Suppl 1974;77:1–73 Google Scholar
31 White, A, O'Reilly, BF. Oral tranexamic acid in the management of epistaxis. Clin Otolaryngol 1988;13:11–16 Google Scholar
32 Hunt, BJ, Allard, S, Keeling, D, Norfolk, D, Stanworth, SJ, Pendry, K; British Committee for Standards in Haematology. A practical guideline for the haematological management of major haemorrhage. Br J Haematol 2015;170:788–803 Google Scholar
33 NHS Blood and Transplant. Education. In: http://hospital.blood.co.uk/patient-services/patient-blood-management/education/ [2 August 2017]Google Scholar